Epidermolysis bullosa (EB) is described in the packet as a group of genetic skin diseases that cause the skin to blister very easily. Blisters form in response to minor injuries or friction, such as rubbing or scratching. Four main types are named: dystrophic epidermolysis bullosa, epidermolysis bullosa simplex, junctional epidermolysis bullosa, and Kindler syndrome. The definition notes that identifying the exact type can be hard because there are many subtypes. The ontology also lists acquired epidermolysis bullosa and inherited epidermolysis bullosa as subtypes.

The defining feature in the packet is skin that blisters very easily after minor injury or friction. Within each type or subtype, a person may be mildly or severely affected, and the definition states that the disease can range from a minor inconvenience to completely disabling, and fatal in some cases. No annotated phenotypes or age-of-onset information are supplied in the packet.

According to the definition, most types of EB are inherited, and the inheritance pattern may be autosomal dominant or autosomal recessive. No specific genes, molecular mechanism, or prevalence figures are certified in this packet, and they are not described here.

Diagnostic methods are not certified in this packet. The definition states only that identifying the exact type can be hard because there are many subtypes.

The packet definition describes management as involving protecting the skin, reducing friction against the skin, and keeping the skin cool. The packet lists one product with current FDA approval and ACTIVE market status: FILSUVEZ (birch triterpenes), approved under an NDA through the FDA Center for Drug Evaluation and Research on 2023-12-18; the orphan-drug listing associates it with an indication of epidermolysis bullosa. Orphan-drug designations are listed for numerous other products; a designation is not an approval and does not establish that a product is in development or available.

Natural history and prognosis are not certified in this packet. The definition notes only that severity varies within each type or subtype, from a minor inconvenience to completely disabling, and fatal in some cases.

Several certified active clinical trial records are present. Examples include NCT06594393 (Phase 2, recruiting), titled 'A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study'; NCT07482787 (Phase 3, recruiting), titled 'Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa'; and NCT07027345 (Phase 2, recruiting), titled 'A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex'. Active clinical trials for this condition are listed on ClinicalTrials.gov.